EA200970108A1 - Композиции и способы для ингибирования роста smad4-дефицитных форм рака - Google Patents
Композиции и способы для ингибирования роста smad4-дефицитных форм ракаInfo
- Publication number
- EA200970108A1 EA200970108A1 EA200970108A EA200970108A EA200970108A1 EA 200970108 A1 EA200970108 A1 EA 200970108A1 EA 200970108 A EA200970108 A EA 200970108A EA 200970108 A EA200970108 A EA 200970108A EA 200970108 A1 EA200970108 A1 EA 200970108A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- smad4
- compositions
- methods
- tumor cells
- tumor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
Настоящее изобретение относится к областям клеточной биологии, иммунологии и онкологии. Изобретение относится к обнаружению существования связи между уровнями экспрессии подавляющего опухоль гена smad4 (также известного как dpc4) и интегрина αβи восприимчивостью групп пациентов к αβ-активным компонентам и композициям (например, антителам и другим лигандам, которые связывают αβ), в частности, раковых клеток этих групп пациентов, и, более конкретно, карцином, таких как карциномы поджелудочной железы. Таким образом, изобретение относится к способам определения восприимчивости опухолевых клеток (в особенности, клеток карцином поджелудочной железы) к таким αβ-активным компонентам и композициям путем исследования экспрессии αβи smad4 клетками опухоли, а также способам диагностики и лечения/предупреждения развития опухоли с применением лигандов, включающих антитела и низкомолекулярные лекарственные средства, которые связываются с интегрином αβна поверхности клеток опухоли и/или которые блокируют один или более компонентов TGF-β-пути, в особенности в smad4-дефицитных опухолевых клетках.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81935906P | 2006-07-10 | 2006-07-10 | |
PCT/US2007/015692 WO2008008315A2 (en) | 2006-07-10 | 2007-07-10 | Compositions and methods for inhibiting growth of smad4-deficient cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200970108A1 true EA200970108A1 (ru) | 2009-12-30 |
Family
ID=38923823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200970108A EA200970108A1 (ru) | 2006-07-10 | 2007-07-10 | Композиции и способы для ингибирования роста smad4-дефицитных форм рака |
Country Status (11)
Country | Link |
---|---|
US (3) | US7927590B2 (ru) |
EP (1) | EP2046374A4 (ru) |
JP (2) | JP2009542810A (ru) |
KR (1) | KR20090027241A (ru) |
CN (1) | CN101563105B (ru) |
AU (1) | AU2007272995B2 (ru) |
BR (1) | BRPI0714381A2 (ru) |
CA (1) | CA2662905A1 (ru) |
EA (1) | EA200970108A1 (ru) |
SG (1) | SG173364A1 (ru) |
WO (1) | WO2008008315A2 (ru) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0308585B8 (pt) | 2002-03-13 | 2021-05-25 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
JP2009542810A (ja) | 2006-07-10 | 2009-12-03 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Smad4欠損癌の増殖を阻害するための組成物および方法 |
WO2009102707A2 (en) * | 2008-02-11 | 2009-08-20 | Auspex Pharmaceuticals, Inc. | Substituted oxazaphosphorines |
IL206678A0 (en) | 2010-06-28 | 2010-12-30 | Hcl Cleantech Ltd | A method for the production of fermentable sugars |
KR101239320B1 (ko) * | 2010-10-25 | 2013-03-06 | (주)파이토엠앤에프 | 여주 추출물을 유효성분으로 포함하는 항암 조성물 |
WO2013025418A1 (en) * | 2011-08-15 | 2013-02-21 | Morehouse School Of Medicine | Delivery system for specifically targeting cancer cells and method of use thereof |
ES2875535T3 (es) | 2012-03-29 | 2021-11-10 | Biogen Ma Inc | Biomarcadores para su uso en aplicaciones de terapia de integrina |
WO2014143739A2 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
US10035859B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
AU2015292678B2 (en) | 2014-07-22 | 2020-10-22 | Cb Therapeutics, Inc. | Anti-PD-1 antibodies |
US10435470B2 (en) | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
AU2018228435A1 (en) | 2017-03-02 | 2019-10-03 | National Research Council Of Canada | TGF-beta-receptor ectodomain fusion molecules and uses thereof |
CA3077213A1 (en) * | 2017-10-04 | 2019-04-11 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
CN111902148A (zh) | 2017-12-06 | 2020-11-06 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
EP3773657A4 (en) * | 2018-03-26 | 2021-12-08 | Altor Bioscience LLC | ANTI-PDL1, IL-15 AND TGF BETA RECEPTOR COMBINATION MOLECULES |
JP7447384B2 (ja) * | 2018-06-21 | 2024-03-12 | オスロ ウニヴェルスィテーツスィーケフース ハーエフ | 方法 |
AU2020289464A1 (en) | 2019-06-06 | 2022-01-20 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
EP4069297A4 (en) | 2019-12-05 | 2024-02-14 | Seagen Inc | ANTI-AVB6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES |
EP4121063A1 (en) | 2020-03-19 | 2023-01-25 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
KR20220097306A (ko) * | 2020-12-30 | 2022-07-07 | 한국과학기술원 | 암전이 억제 및 항암제 감수성 증진용 조성물 |
CN115215943B (zh) * | 2021-04-16 | 2023-04-14 | 中国科学院化学研究所 | 一种有机室温磷光高分子材料及其制备方法和应用 |
CA3231330A1 (en) | 2021-09-16 | 2023-03-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US5223493A (en) | 1984-12-28 | 1993-06-29 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
US5962643A (en) | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
US6307026B1 (en) | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
US5420120A (en) | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
DE69531187T2 (de) | 1994-12-20 | 2004-04-22 | Merck Patent Gmbh | Monoklonaler Antikörper gegen das Alpha-V-Integrin |
US5688960A (en) | 1995-05-02 | 1997-11-18 | Schering Corporation | Substituted oximes, hydrazones and olefins useful as neurokinin antagonists |
US5795894A (en) | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
US5696267A (en) | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
US5719156A (en) | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US5654316A (en) | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
HUP9901673A3 (en) | 1995-08-17 | 2001-06-28 | Scil Biomedicals Gmbh | Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage |
AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
CN101333516A (zh) | 1995-08-29 | 2008-12-31 | 麒麟医药株式会社 | 嵌合体动物及其制备方法 |
US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
CA2257357C (en) | 1996-06-07 | 2010-04-13 | Neorx Corporation | Humanized antibodies with modified glycosylation |
AU6721696A (en) * | 1996-07-15 | 1998-03-06 | Human Genome Sciences, Inc. | Cd44-like protein |
US5789422A (en) | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
US5783579A (en) | 1996-12-20 | 1998-07-21 | Schering Corporation | Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists |
ES2311131T3 (es) | 1997-08-08 | 2009-02-01 | The Regents Of The University Of California | Tratamiento de la fibrosis hepatico con anticuerpos contra la integrina alfa-v-beta6. |
JP2002501086A (ja) | 1998-01-23 | 2002-01-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗−αvインテグリンモノクローナル抗体および、フィブロネクチンへのαvβ6インテグリンの付着を阻害するためのその使用 |
CN1335853A (zh) | 1998-12-19 | 2002-02-13 | 默克专利股份公司 | 整联蛋白αvβb的抑制剂 |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
DE10063173A1 (de) | 2000-12-18 | 2002-06-20 | Merck Patent Gmbh | Harnstoff- und Urethanderivate |
UA83791C2 (ru) | 2001-04-13 | 2008-08-26 | Байоджен Айдек Ма Инк. | Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 |
DE10118550A1 (de) | 2001-04-14 | 2002-10-17 | Merck Patent Gmbh | Liganden des Integrins alpha¶nu¶beta¶6¶ |
GB2380127A (en) | 2001-09-26 | 2003-04-02 | Isis Innovation | Treatment of chronic joint inflammation |
BR0307975A (pt) | 2002-02-25 | 2005-01-11 | Elan Pharm Inc | Métodos para reduzir cronicamente a inflamação patológica em um paciente e para determinar a eficácia de um regime de administração crÈnica para tratar inflamação patológica em um indivìduo, composição e terapia combinada para tratamento crÈnico de inflamação patológica em um paciente e uso de um inibidor de alfa-4-integrina |
BRPI0308585B8 (pt) | 2002-03-13 | 2021-05-25 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna |
US20090028853A1 (en) | 2006-10-19 | 2009-01-29 | The Regents Of The University Of California, A California Corporation | TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN ALPHAvBETA6 |
AU2003230929A1 (en) * | 2002-04-12 | 2003-10-27 | Raven Biotechnologies, Inc. | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
WO2003097615A1 (en) | 2002-05-17 | 2003-11-27 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS |
AU2003298783B2 (en) | 2002-11-26 | 2010-11-04 | Abbvie Biotherapeutics Inc. | Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis |
US20040253311A1 (en) | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
CA2544855A1 (en) | 2003-11-04 | 2005-05-19 | Bayer Pharmaceuticals Corporation | Immunohistochemical methods |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
JP2009542810A (ja) | 2006-07-10 | 2009-12-03 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Smad4欠損癌の増殖を阻害するための組成物および方法 |
GB0803192D0 (en) | 2008-02-22 | 2008-04-02 | Mubio Products Bv | SCLC biomarker panel |
US20140045915A1 (en) | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
-
2007
- 2007-07-10 JP JP2009519483A patent/JP2009542810A/ja not_active Withdrawn
- 2007-07-10 SG SG2011050325A patent/SG173364A1/en unknown
- 2007-07-10 AU AU2007272995A patent/AU2007272995B2/en active Active
- 2007-07-10 EA EA200970108A patent/EA200970108A1/ru unknown
- 2007-07-10 EP EP07810296A patent/EP2046374A4/en not_active Withdrawn
- 2007-07-10 BR BRPI0714381-8A patent/BRPI0714381A2/pt not_active IP Right Cessation
- 2007-07-10 CN CN2007800260897A patent/CN101563105B/zh active Active
- 2007-07-10 US US11/822,859 patent/US7927590B2/en not_active Ceased
- 2007-07-10 CA CA002662905A patent/CA2662905A1/en not_active Abandoned
- 2007-07-10 WO PCT/US2007/015692 patent/WO2008008315A2/en active Search and Examination
- 2007-07-10 KR KR1020097000498A patent/KR20090027241A/ko not_active Application Discontinuation
-
2011
- 2011-04-18 US US13/088,774 patent/US20110293512A1/en not_active Abandoned
-
2012
- 2012-11-15 JP JP2012251220A patent/JP2013039140A/ja not_active Withdrawn
-
2013
- 2013-04-16 US US13/863,646 patent/USRE44681E1/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2009542810A (ja) | 2009-12-03 |
USRE44681E1 (en) | 2013-12-31 |
JP2013039140A (ja) | 2013-02-28 |
WO2008008315A3 (en) | 2008-12-11 |
US20110293512A1 (en) | 2011-12-01 |
BRPI0714381A2 (pt) | 2013-03-05 |
SG173364A1 (en) | 2011-08-29 |
EP2046374A4 (en) | 2010-05-05 |
KR20090027241A (ko) | 2009-03-16 |
AU2007272995A1 (en) | 2008-01-17 |
WO2008008315A2 (en) | 2008-01-17 |
AU2007272995B2 (en) | 2013-02-07 |
CN101563105B (zh) | 2013-01-23 |
CN101563105A (zh) | 2009-10-21 |
US7927590B2 (en) | 2011-04-19 |
EP2046374A2 (en) | 2009-04-15 |
US20080317667A1 (en) | 2008-12-25 |
CA2662905A1 (en) | 2008-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200970108A1 (ru) | Композиции и способы для ингибирования роста smad4-дефицитных форм рака | |
CY1124965T1 (el) | Μονοκλωνα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου | |
Koulis et al. | Personalized medicine—current and emerging predictive and prognostic biomarkers in colorectal cancer | |
EA200801171A1 (ru) | Биспецифичные лиганды, обладающие специфичностью связывания с поверхностными клеточными мишенями, и способы их применения | |
NZ593289A (en) | Anti-neuropilin-1 antibodies for treating angiogenesis | |
TW200626900A (en) | Wnt proteins and detection and treatment of cancer | |
EA200800278A1 (ru) | АНТИ-αβ-АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ | |
EA201100779A1 (ru) | Композиции антител к cxcr1 и способы их применения | |
UA99701C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1) | |
EA200800094A1 (ru) | Антитела cd19 и их использование | |
WO2007133822A8 (en) | Gitr antibodies for the treatment of cancer | |
DE602004015811D1 (de) | Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden | |
EA200702361A1 (ru) | АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ | |
WO2005113816A3 (en) | Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer | |
EA200870020A1 (ru) | Человеческие моноклональные антитела против о8е | |
WO2005080431A3 (en) | Monoclonal antibodies that specifically bind to folate receptor alpha | |
WO2005084109A3 (en) | Cancer specific gene mh15 | |
EA201390744A1 (ru) | Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований | |
DE602006005084D1 (de) | Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen | |
UA99602C2 (ru) | Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток | |
CY1122156T1 (el) | Αντισωματα κατα του σχετιζομενου με τον νεφρο αντιγονου 1 και αντιγονοδεσμευτικα θραυσματα αυτων | |
ATE504602T1 (de) | Für humane matriptase spezifische bindungsproteine | |
EA201101516A1 (ru) | Антитела, специфические для кадгерина-17 | |
EA201300470A1 (ru) | Антитела | |
WO2009019365A3 (fr) | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal |